TP53 and breast carcinoma: Therefore, EDI was independent of known cancer hallmarks and can co-define an aggressive subgroup of high-grade breast cancer together with TP53 mutation (Fig 4B), highlighting the need to study genetic alterations in the context of the heterogeneity of the tumor microenvironment [3,29,30].